Drugs / LETOLIZUMAB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03605927 | Feb 2019 → Jul 2023 | acute graft versus host disease | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02273960 | Nov 2014 → Jan 2018 | autoimmune thrombocytopenic purpura | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LETOLIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989999 ↗ |
| Known as | BMS-986004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03605927 ↗ |
| Action | Inhibit | “CD40L blockade” NCT03605927 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3989999 ↗ |
| Route | Intravenous | “BMS-986004 solution intravenously (IV) as specified” NCT02273960 ↗ |